Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs.... [Read more at source]